Recent advances in promising drugs for primary prevention of gastroesophageal variceal bleeding with cirrhotic portal hypertension

作     者：Ji-Yao Sheng Zi-Fan Meng Qiao Li Yong-Sheng Yang Ji-Yao Sheng;Zi-Fan Meng;Qiao Li;Yong-Sheng Yang

作者机构：Department of Hepatobiliary and Pancreatic Surgerythe Second Hospital of Jilin UniversityChangchun 130041China Jilin Engineering Laboratory for Translational Medicine of Hepatobiliary and Pancreatic Diseasesthe Second Hospital of Jilin UniversityChangchun 130041China 

出 版 物：《Hepatobiliary & Pancreatic Diseases International》 (国际肝胆胰疾病杂志（英文版）)

年 卷 期：2024年第23卷第1期

页      面：4-13页

核心收录：

学科分类：1002[医学-临床医学] 10[医学] 

基　　金：This work was supported by grants from the National Natural Science Foundation of China(81902484) China Postdoctoral Science Foundation(2020M670864) Youth Support Project of Jilin Association for Science and Technology(202028) Jilin Provincial Health Special Project(2020SCZT039) Jilin Health and Healthy Youth Science and Technology Training Plan(2020Q017). 

主　　题：Cirrhotic portal hypertension Target drug Primary prevention Bleeding 

摘      要：Background:Gastroesophageal variceal bleeding is one of the most severe complications of patients with cirrhosis.Although primary prevention drugs,including non-selectiveβ-blockers,have effectively reduced the incidence of bleeding,their efficacy is limited due to side effects and related contraindications.With recent advances in precision medicine,precise drug treatment provides better treatment efficacy.Data sources:Literature search was conducted in PubMed,MEDLINE and Web of Science for relevant articles published up to May 2022.Information on clinical trials was obtained from https://clinicaltrials.gov/and http://***/.Results:The in-depth understanding of the pathogenesis and advances of portal hypertension has enabled the discovery of multiple molecular targets for promising drugs.According to the site of action,these drugs could be classified into four classes:intrahepatic,extrahepatic,both intrahepatic and extrahepatic targets and others.All these classes of drugs offer advantages over traditional treatments in prevention of gastroesophageal variceal bleeding in patients with cirrhotic portal hypertension.Conclusions:This review classified and summarized the promising drugs,which prevent gastroesophageal variceal bleeding by targeting specific markers of pathogenesis of portal hypertension,demonstrating the significance of using the precision medicine strategy to discover and develop promising drugs for the primary prevention of gastroesophageal variceal bleeding in patients with cirrhotic portal hypertension.